Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2014-005317-23-GB
EUCTR2014-005317-23-GB
Active, not recruiting
Phase 1

Effects of ultra-long acting bronchodilator therapy assessed by impulse oscillometry in smoking asthmatics taking inhaled corticosteroids - MAN05 Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics

Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside0 sites16 target enrollmentAugust 11, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsStriverdi RespimatSpiriva Respimat

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
Enrollment
16
Status
Active, not recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 11, 2015
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside

Eligibility Criteria

Inclusion Criteria

  • •Male or female volunteers aged 18\-65 years with persistent asthma and on inhaled corticosteroids (at least 400 micrograms BDP or the equivalent daily)
  • •Current smoker
  • •FEV1 \> 60 % predicted
  • •Ability to give informed consent
  • •Agreement for their GP to be made aware of study participation and to receive feedback as relevant to the participant’s well being
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 16
  • •F.1\.3 Elderly (\>\=65 years) no

Exclusion Criteria

  • •Other respiratory diseases such as COPD, bronchiectasis or ABPA
  • •An asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month of the study commencement or 3 months if hospital admission was required
  • •Any clinically significant medical condition that may endanger the health or safety of the participant
  • •Participation in another trial within 30 days before the commencement of the study
  • •Pregnancy or lactation
  • •Unable to comply with the procedures of the protocol
  • •Unable or unwilling to consent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Efficacy of long-acting bronchodilators on dynamic lung hyperinflation in chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease (COPD)
JPRN-UMIN000027446Shinshu University School of Health Sciences30
Completed
Phase 4
Ultra-long Acting Bronchodilator Therapy in Smoking AsthmaticsAsthma
NCT02682862University of Dundee17
Completed
Not Applicable
Effects of a newly bronchodilator for lung hyperinflation and exercise tolerance in patients with mild to moderate stable COPDCOPD
JPRN-UMIN000009857Kurume University School of Medicine18
Completed
Not Applicable
Additive effects of short-acting bronchodilators in COPD patients who still had dyspnea in their daily lives despite long-acting bronchodilators.Chronic obstructive pulmonary disease
JPRN-UMIN000003192Department of Biomedical Laboratory Sciences, Shinshu University School of Health Sciences.60
Completed
Not Applicable
The effect of prophylactic bronchodilator treatment with transdermal tulobuterol patch on lung compliance and airway resistanceDiseases of th respiratory system
KCT0001152Pusan National University Hospital82